LW402
/ Longwood Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 28, 2026
Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis
(clinicaltrials.gov)
- P3 | N=480 | Not yet recruiting | Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd.
New P3 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
September 23, 2025
Phase II Study of LW402 in Moderate-to-Severe Atopic Dermatitis
(clinicaltrials.gov)
- P2 | N=144 | Completed | Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd.
New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
1 to 2
Of
2
Go to page
1